PBM in iAMDNCT07554690
Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 20 words
- Start date changed from estimate of Oct 2026 to Oct 9, 2026
- Secondary endpoints: details revised at 2 of 9 entries
- Site details revised
- Notable Start date: Jun 1, 2026 to Oct 2026v3
- Minor Secondary endpoints: 5 to 9v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Participants assigned to this arm will receive photobiomodulation (PBM) therapy using a CE-marked medical device. Treatment is delivered in two cycles: the first cycle consists of 8 sessions over 4 weeks (two sessions per week), and the second cycle consists of 6 sessions over 3 weeks. Each session lasts approximately 12 minutes and includes exposure to specific wavelengths of light under standardized conditions.
Participants assigned to this arm will undergo sham treatment following the same schedule and procedures as the active treatment group, including identical session frequency and duration. The device delivers minimal, non-therapeutic light energy, ensuring no active photobiomodulation effect while maintaining masking conditions.
Procedures: Photobiomodulation Therapy, Sham Photobiomodulation
Sites
1 site in 1 country
- IRCCS Fondazione G.B.Bietti c/o Ospedale BritannicoRoma, Italy, Italy